Skip to content

Study · Randomized controlled trial · n = 1,464 · 2025

5 results

Efficacy of 1 L Polyethylene Glycol Plus Ascorbic Acid With Linaclotide Versus Senna for Bowel Preparation: A Multicenter, Endoscopist-Blinded, Randomized Controlled Trial (Apple Trial).

Maeda N, Maeda N, Higashimori A, Kabata D, Yamamoto I, Yanagida T, Yanagida T, Kin D, Matsumoto Y, Nakata R, Hashimoto A, Sawada A and 17 more

Show all authors

Maruyama H, Okamoto J, Katsuno T, Nadatani Y, Ominami M, Fukunaga S, Morimoto K, Hosomi S, Tanaka F, Nakatani M, Taira K, Sasaki E, Fukuda T, Ota K, Yoshida H, Watanabe T, Fujiwara Y

The American journal of gastroenterology25 Feb 2025Cited by 6 (Europe PMC)

PMID39996602 (opens in a new tab)PMCIDPMC12570610 (opens in a new tab)DOI10.14309/ajg.0000000000003370 (opens in a new tab)PepBankPUB-39996602
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In colonoscopy outpatients, adequate preparation was higher with linaclotide than senna on identical PEG-Asc background, at 92% versus 86% (P = 0.001).

    In plain wordsIn colonoscopy outpatients, linaclotide produced higher adequate preparation rates than senna with the same PEG-Asc background.

    Peptide
    Linaclotide
    Outcome
    IncreaseAdequate bowel preparation
    Study

    n = 1,464

    Comparator
    Senna 24 mg with 1 L PEG-Asc
    Analysis
    Primary
    Outcome group
    Bowel Preparation · Gastrointestinal
    Studied dose
    0.5 mgAs given in this study (human).

    Measurements

    Adequate preparation
    92%
    linaclotide
    Adequate preparation
    86%
    senna
    P value
    0.001 NA
    between groups

    Source sentences

    Summary
    The 1L-PEG/AL demonstrated higher adequate BP rates (92% vs 86%, P = 0.001) compared with 1L-PEG/AS.
    3 context sentences
    Summary · context
    The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc.
    Summary · context
    A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy.
    Summary · context
    Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733).
  2. 02HumanRandomized controlled trialSafety outcome

    In colonoscopy outpatients, adverse events were similar with linaclotide and senna on identical PEG-Asc background.

    In plain wordsIn colonoscopy outpatients, adverse events were similar with linaclotide and senna with the same PEG-Asc background.

    Peptide
    Linaclotide
    Outcome
    Direction not reportedAdverse events
    Study

    n = 1,464

    Comparator
    Senna 24 mg with 1 L PEG-Asc
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.5 mgAs given in this study (human).

    Source sentences

    Summary
    Both groups experienced similar adverse events and expressed high willingness for repeat BP (83% vs 81%, P = 0.49).
    3 context sentences
    Summary · context
    The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc.
    Summary · context
    A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy.
    Summary · context
    Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In colonoscopy outpatients, willingness to repeat preparation was similar, 83% with linaclotide versus 81% with senna on PEG-Asc background (P = 0.49).

    In plain wordsIn colonoscopy outpatients, willingness to repeat preparation was similar with linaclotide (83%) and senna (81%) with the same PEG-Asc background.

    Peptide
    Linaclotide
    Outcome
    No significant changeWillingness for repeat preparation
    Study

    n = 1,464

    Comparator
    Senna 24 mg with 1 L PEG-Asc
    Outcome group
    Treatment Acceptability · Gastrointestinal
    Studied dose
    0.5 mgAs given in this study (human).

    Measurements

    Willingness
    83%
    linaclotide
    Willingness
    81%
    senna
    P value
    0.49 NA
    between groups

    Source sentences

    Summary
    Both groups experienced similar adverse events and expressed high willingness for repeat BP (83% vs 81%, P = 0.49).
    3 context sentences
    Summary · context
    The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc.
    Summary · context
    A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy.
    Summary · context
    Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In high-risk colonoscopy patients, adequate preparation was higher with linaclotide than senna on PEG-Asc background, at 94% versus 86% (P < 0.001).

    In plain wordsIn high-risk colonoscopy patients, linaclotide produced higher adequate preparation rates than senna with the same PEG-Asc background.

    Peptide
    Linaclotide
    Outcome
    IncreaseAdequate preparation in high-risk patients
    Study

    n = 892

    Comparator
    Senna 24 mg with 1 L PEG-Asc
    Outcome group
    Bowel Preparation · Gastrointestinal
    Studied dose
    0.5 mgAs given in this study (human).

    Measurements

    Adequate preparation
    94%
    linaclotide; high risk
    Adequate preparation
    86%
    senna; high risk
    P value
    < 0.001 NA
    high risk

    Source sentences

    Summary
    In high-risk patients (n = 892), 1L-PEG/AL had significantly higher adequate BP rates (94% vs 86%, P < 0.001), whereas rates were comparably high in low-risk patients (n = 539) (94% vs 94%, P = 0.66).
    3 context sentences
    Summary · context
    The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc.
    Summary · context
    A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy.
    Summary · context
    Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In low-risk colonoscopy patients, adequate preparation was 94% with both linaclotide and senna on PEG-Asc background (P = 0.66).

    In plain wordsIn low-risk colonoscopy patients, linaclotide and senna produced comparable adequate preparation rates with the same PEG-Asc background.

    Peptide
    Linaclotide
    Outcome
    No significant changeAdequate preparation in low-risk patients
    Study

    n = 539

    Comparator
    Senna 24 mg with 1 L PEG-Asc
    Outcome group
    Bowel Preparation · Gastrointestinal
    Studied dose
    0.5 mgAs given in this study (human).

    Measurements

    Adequate preparation
    94%
    both groups; low risk
    P value
    0.66 NA
    low risk

    Source sentences

    Summary
    In high-risk patients (n = 892), 1L-PEG/AL had significantly higher adequate BP rates (94% vs 86%, P < 0.001), whereas rates were comparably high in low-risk patients (n = 539) (94% vs 94%, P = 0.66).
    3 context sentences
    Summary · context
    The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc.
    Summary · context
    A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy.
    Summary · context
    Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.